Geographic atrophy
Drug research and approvals for geographic atrophy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 45 studies of geographic atrophy are recruiting on ClinicalTrials.gov, and Health Canada has authorized 2 drug trials for it since 2013.
- Recruiting worldwide: 45
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
- A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related…NCT07851259 · Phase 2 · Genentech, Inc. · starts Jan 8, 2027
- Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMDNCT07770828 · Phase 3 · Ocugen · starts Aug 11, 2026
- A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic AtrophyNCT07668804 · Phase 1 / Phase 2 · Theratocular Biotek Co. · starts Jun 2, 2026
- A Study in Adults With Geographic AtrophyNCT07606365 · Phase 2 · Sitala Bio LTD · starts Sep 11, 2026
- Phase 1 Study of C.001 in Retinal DegenerationNCT07594236 · Phase 1 · Cellio Therapeutics Inc · starts Apr 7, 2026
- Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA).NCT07582042 · Not reported · University of Utah · starts Jun 15, 2026
- Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot StudyNCT07556406 · Not reported · University of California, San Francisco · starts Jun 11, 2025
- Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic AtrophyNCT07531927 · Not applicable · Okuvision GmbH · starts May 5, 2026
- Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited…NCT07502664 · Not reported · Ray Therapeutics, Inc. · starts Feb 19, 2026
Phase 3 5
- LampalizumabComplement factor D inhibitor
- PegcetacoplanComplement C3 inhibitor
- Avacincaptad pegol
- Retinol
- Tinlarebant
Phase 2 12 of 15
- EmixustatRetinoid isomerohydrolase inhibitor
- Galegenimab
- SirolimusFK506-binding protein 1A inhibitor
- GSK933776Amyloid-beta A4 protein binding agent
- TesidolumabComplement C5 binding agent
- Lusacomfar alfa
- Sefaxersen sodium
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- LidocaineSodium channel alpha subunit blocker
- PrednisoneGlucocorticoid receptor agonist
- TriamcinoloneGlucocorticoid receptor agonist
- AL-78898AComplement C3 inhibitor
Phase 1 or earlier 2
How its trials ended
144 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 45 whose ending is known, 20% met their primary endpoint, 13% missed it and 67% stopped early.
- Completed, result not reported4833%
- Ongoing4229%
- Stopped: other or unclear1510%
- Met its primary endpoint96%
- Stopped: lack of efficacy96%
- Status unknown96%
- Missed its primary endpoint64%
- Stopped: sponsor or business decision53%
- Stopped: funding11%
| Feb 6, 2026 | A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in participants with…FWY003 | Novartis Pharmaceuticals | Ongoing |
| May 16, 2025 | A phase 2 multicenter, randomized, double-masked, sham controlled, reference-arm study to evaluate efficacy and safety of ONL1204 in patients with geographic…ONL1204 | ONL Therapeutics | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA